References

Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma

10.1001/jamanetworkopen.2022.16199 · ExternalCitation · doi-reference

NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis

10.1001/jamanetworkopen.2023.50756 · ExternalCitation · doi-reference

Risk‐of‐bias VISualization (robvis): an R package and Shiny web app for visualizing risk‐of‐bias assessments

10.1002/jrsm.1411 · ExternalCitation · doi-reference

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study

10.1016/j.ejca.2021.03.028 · ExternalCitation · doi-reference

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials

10.1016/j.ejca.2023.112945 · ExternalCitation · doi-reference

NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data

10.1016/j.esmoop.2025.105827 · ExternalCitation · doi-reference

A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC)

10.1016/j.hpb.2019.12.001 · ExternalCitation · doi-reference

Addressing the challenges of pancreatic cancer: future directions for improving outcomes

10.1016/j.pan.2014.10.001 · ExternalCitation · doi-reference

The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort study

10.1016/j.pan.2022.11.005 · ExternalCitation · doi-reference

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(23)01366-1 · ExternalCitation · doi-reference

Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis

10.1016/s1470-2045(24)00511-4 · ExternalCitation · doi-reference

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

10.1016/s2468-1253(20)30330-7 · ExternalCitation · doi-reference

Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer

10.1038/s41572-026-00699-6 · ExternalCitation · doi-reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

10.1056/nejmoa1011923 · ExternalCitation · doi-reference

Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review

10.1080/14796694.2024.2435253 · ExternalCitation · doi-reference

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

10.1080/14796694.2026.2664776 · ExternalCitation · doi-reference

Comparison of FOLFIRINOX and gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: using Korean pancreatic cancer (K-PaC) registry

10.1097/coc.0000000000000730 · ExternalCitation · doi-reference

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

10.1136/bmj.i4919 · ExternalCitation · doi-reference

IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves

10.1186/s12874-021-01308-8 · ExternalCitation · doi-reference

Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis

10.1186/s12876-023-02853-w · ExternalCitation · doi-reference

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

10.1186/s12885-023-11377-1 · ExternalCitation · doi-reference

Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer

10.1200/jco.19.01124 · ExternalCitation · doi-reference

Devimistat (CPI-613) with modified fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: the phase III AVENGER 500 study

10.1200/jco.23.02659 · ExternalCitation · doi-reference

Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: The randomized phase II CISPD3 trial: Q. Fu et al

10.1245/s10434-023-13383-w · ExternalCitation · doi-reference

Early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma using circulating tumor DNA

10.26502/jsr.10020173 · ExternalCitation · doi-reference

Correlative analysis of tumor-informed circulating tumor DNA (ctDNA) and the survival outcomes of patients with pancreatic adenocarcinoma

10.3390/biomedicines13051124 · ExternalCitation · doi-reference

Real-life results of palliative chemotherapy in metastatic pancreatic ductal adenocarcinoma

10.3390/cancers15133500 · ExternalCitation · doi-reference

Pancreatic ductal adenocarcinoma (PDAC): a review of recent advancements enabled by artificial intelligence

10.3390/cancers16122240 · ExternalCitation · doi-reference

Impact of tumor location on survival outcomes in pancreatic head versus body/tail cancer: Institutional experience

10.3390/cancers17111777 · ExternalCitation · doi-reference

An 81-year-old geriatric patient with metastatic pancreatic cancer demonstrating excellent response and well tolerance to NALIRIFOX: A case report and literature review

10.3390/reports8020069 · ExternalCitation · doi-reference

Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas

10.5114/wo.2023.127013 · ExternalCitation · doi-reference

Pancreatic tumorigenesis: Precursors, genetic risk factors and screening

10.5772/intechopen.110887 · ExternalCitation · doi-reference

NCCN Guidelines® Insights: Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate, Version 2.2026: Featured updates to the NCCN Guidelines

10.6004/jnccn.2026.0007 · ExternalCitation · doi-reference